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tion. ConClusions: The dimensions excluding Ability of act all had the higher 
sensitivity on AIMS2-2F scale, which means overall sensitivity was better than 
SF-6D . Therefore, EQ-5D is more suitable for the evaluation of the QOL of patients 
with osteoarthritis. But the Psychological health dimension of SF-6D showed 
strong sensitivity, which prompts us Psychological problems are the important 
factors influencing the Osteoarthritis patients life quality.
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objeCtives: Biologic treatments have improved outcome for immunology diseases 
in the last decades globally. However, biologic penetration in China is lower com-
pared to developed countries. This study aims to explore the willingness-to-pay 
(WTP) for biologics in immunology diseases in China by understanding decisions 
driving physicians’ prescribing behavior and patients’ payment. Methods: Primary 
market research was done by interviewing 160 physicians with biologic experience, 
200 patients consisting of patients who have not received any biologic treatments 
before (bio-naïve), and patients with biologic experience (bio-experienced) from 
large hospitals (tier 3A) in Tier 1 and 2 cities. Patients were recruited with a diverse 
set of affordability as measured by household incomes. Results: The results show 
that patients rely on physicians for treatment recommendation. For rheumatoid 
arthritis, ankylosing spondylitis, and psoriasis, the top four factors driving physi-
cian’s recommendation are drug cost, patients’ ability-to-pay, safety of treatment 
and efficacy of treatment. For Ulcerative Colitis (UC) and Crohn’s Disease (CD), the 
top four factors were safety, efficacy, patients’ affordability followed by drug cost. 
The difference in pattern for UC and CD is likely attributed to the more severe 
nature of these diseases. Other factors such as injection frequency and mode of 
administration ranked lower for all indicators. ConClusions: Patients interview 
results show that ≈60% of bio-naïve patients were rejected biologic treatment due 
to cost; ≈30% of bio-experienced patients stopped biologic treatments due to cost. 
This confirms that affordability considerations do limit the potential benefit that 
biologic treatments can provide. Interestingly, ≈30% of bio-experienced patients 
have stopped biologic treatment as it was perceived that treatment course was 
completed. This could be attributed to how physicians perceive biologics to be used. 
While affordability limits biologic penetration in auto-immune diseases in China, 
there are other considerations e.g. the severity of diseases and physician perception 
of treatment paradigm.
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objeCtives: Use of innovative medicines in oncology and immunology is relatively 
lower in China compared to developed countries. This study aims to explore the 
willingness-to-pay (WTP) for these two therapeutic areas by understanding decisions 
driving physicians’ prescribing behavior and patients’ payment in immune diseases 
(rheumatoid arthritis, ankylosing spondylitis, and psoriasis) and oncology (prostate 
cancer). Methods: For immunology, primary market research was done by inter-
viewing 160 physicians with biologic experience, 200 patients consisting of patients 
who have not received any biologic treatments before (bio-naïve), and patients with 
biologic experience (bio-experienced). For oncology, 50 physicians and 40 patients 
were recruited. All physicians and patients were recruited from large hospitals (tier 
3A) from Tier 1, 2 cities. Patients were recruited to represent a diverse set of afford-
ability. Results: The results show that patients rely on physicians for treatment 
recommendation. For rheumatoid arthritis, ankylosing spondylitis, and psoriasis, the 
top four factors driving physician’s recommendation are drug cost, patients’ ability-
to-pay, safety of treatment and efficacy of treatment. For Ulcerative Colitis (UC) and 
Crohn’s Disease (CD), the top four factors were safety, efficacy, patients’ affordability 
followed by drug cost. The difference in pattern for UC and CD is likely attributed to 
the more severe nature of these diseases. Other factors such as injection frequency 
and mode of administration ranked lower for all indicators. For oncology, the top 
factors driving physician prescription are efficacy (overall survival, progression-free 
survival) followed by safety and tolerability. Patient affordability and drug cost are 
ranked much lower. Similarly, from patients interview results, efficacy was rated 
more important than cost as a factor driving willingness-to-pay. ConClusions: 
Observations from these two therapy areas show that cost and affordability are the 
top considerations when the diseases are less severe. For severe diseases and life-
threatening diseases, efficacy and safety of the drug are rated more than drug cost.
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objeCtives: Between 2011 and 2015, 32 biologics valued at more than $55 bil-
lion are expected to lose patent protection across the world (Datamonitor 2011). 
The biologics patent cliff has presented a huge opportunity for biosimilar manu-
facturers. In the context of this growing biosimilars market, this research aimed 
to investigate the regulatory environments and the evidence (clinical, economic 
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objeCtives: To observe the clinical efficacy and economic value of Qin Xi-tong(QXT) 
during the long-term treatment for patients of RA. Methods: Caulis Sinomenii(CS) 
has been recognized as an effective medicinal plant for arthritis. The Fifth Hospital 
of Xi’an developed water extract from CS to a novel kind of drug naming QXT. RA was 
diagnosed in 200 patients referred to Department of Rheumatology. All the patients 
were classified according to their different areas. They were respectively evaluated 
by the score of VAS, DAS28 and the response rates of ACR20/70 .We also follow up 
the patients for the usage rate, treatment compliance and satisfaction of QXT. We 
count the cost of patients and the income of self-made chinese traditional medicine 
in our hospital to measure the economic value of QXT. Results: We found that: 1) 
There were 140 out of 200 patients who were from 14 provinces of China with RA 
using QXT.2. Percentage of the satisfaction and compliance with the treatment of 
QXT+MTX group were higher than MTX group, satisfaction rates (94.2% vs. 67.1%, 
X2= 11.7, P< 0.01) ,compliance rates (91.4% vs. 62.9%, X2= 16.2, P< 0.01) , respectively. 
3)statistical result of year 2 showed : Compared with pretherapy,QXT+ MTX group 
scored significantly lower of VAS, while achieving higher level of ACR20 and ACR70 . 
4)QXT was safe and well tolerated in this trial, difference of adverse events was not 
statistically significant. 5)The statistics showed the mean cost for QXT only occupied 
9.2%(78/856)of patient’s expenses for the treatment of RA. ConClusions: It is the 
first time to study the economic value of QXT in a randomized clinical trial for 2 
years. QXT+MTX could contribute to the higher clinical remission rates of patients 
with RA. It is worth noting that Chinese patients with RA was much better satisfied 
and complying with QXT which is actually consistent with our clinical practice.
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objeCtives: This study aims to identify the care needs for rheumatoid arthritis (RA) 
from patient perspectives. Methods: One-on-one in-depth interviews were con-
ducted with selected patients with RA in March 2014 in Singapore General Hospital 
as part of a larger ongoing study. The interviews were performed by a trained soci-
ologist following an interview guide allowing free probes. Each Interview lasted for 
20-60 minutes. 16 interviews were audio-recorded and transcribed with written 
consent from the patients. Notes were taken for the three unrecorded interviews. 
The transcripts and notes were analysed using NVivo 10 to identify major areas 
of patient-reported care needs. Results: 19 patients (11 Chinese, 2 Malays, and 6 
Indians; 17 females; age: 25-67 years; median educational level: higher secondary 
school) with 1-38 years of RA were interviewed. 15 had accepted that they would 
need lifelong RA medication; three were still testing if they could live without medi-
cation through self-experimentation; and one was in denial of the diagnosis. In 
additional to medical treatment, three other areas of care needs were identified: 
first, the need for knowledge about RA and its self-management (n= 17) ; second, 
the need for peer support to learn “how other people live with RA” (n= 11); and 
third, the need for psycho-emotional support to manage the emotional problems 
accompanying RA diagnosis (n= 9). These needs were most acute upon diagnosis 
and became less important once the patient had established new normality of life 
after having RA (e.g. avoiding things one cannot do due to RA without feeling bad, 
taking RA medication without feeling being hassled). ConClusions: The results 
of this study suggest that RA patients’ care needs are multidimensional and time 
sensitive. A muti-pronged approach including drug therapy, and patient education, 
support, and counselling is needed from start of treatment to help patients form 
the new normality of their lives.
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objeCtives: As the universal scales, EQ-5D and SF-6D have been widely used 
in the evaluation of the quality of life(QOL) of patients with many kinds of dis-
ease including Osteoarthritis. But as to which scale is much more suitable for the 
Osteoarthritis patients evaluation , there is scarcely any research so far. The cur-
rent study aimed to compare the correlation of the EQ -5D, SF-6D with AIMS2-2F 
scale, the specificity scale of QOL evaluation, then to determine the suitability of 
two scale for the QOL of patients with Osteoarthritis. Methods: From April to 
December in 2012, 100 patients with Osteoarthritis were enrolled with consent 
at Orthopedic Clinic in the First Affiliated Hospital of Chinese Medical University. 
They filled out the EQ-5D, SF-6D, and AIMS2 2F scales successively by themselves 
. SPSS19.0 analysis software was used to deal with the collected data, parts of the 
lack data were eliminated automatically . Cronbach alpha coefficient evaluated 
the internal consistency of scales. Pearson, Speaman and Kendall’s tau-b correla-
tion coefficient analysis were used to test the reliability between EQ-5D, SF-6D 
and AIMS2-2F score data. On the scale of the response and the factors affecting 
the QOL, we use multiple stepwise regression analysis, significant test of bilat-
eral boundary value point. Results: 77 sets of valid survey scale were analyst 
EQ-5D, SF-6D, and AIMS2-2F scales all had good internal consistency showing good 
reliability with the crowns Bach coefficient were all higher than 0.6.During the 
various dimensions of EQ-5D scale, Anxiety, Pain, Daily life and Self care showed 
the higher sensitivity on AIMS2-2F scale. Followed by Ability to act . As to SF-6D 
scale, Psychological health, Vitality, and Social function showed higher sensitiv-
ity on AIMS2-2F scale. And followed by Role constraints, Pain and Physical func-
